UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Placebo and nocebo responses in restless legs syndrome: A systematic review and meta-analysis.
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Article
  • Authors:
    Silva MA, Duarte GS, Camara R, Rodrigues FB, Fernandes RM, Abreu D, Mestre T, Costa J, Trenkwalder C, Ferreira JJ
  • Publication date:
    10/05/2017
  • Journal:
    Neurology
  • Medium:
    Print-Electronic
  • Print ISSN:
    0028-3878
  • Language:
    eng
  • Addresses:
    From the Laboratory of Clinical Pharmacology and Therapeutics (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Portuguese Collaborating Center of the IberoAmerican Cochrane Network, Cochrane Portugal (G.S.D., R.M.F., J.C.), and Center for Evidence-Based Medicine (J.C.), Faculty of Medicine, University of Lisbon; Clinical Pharmacology Unit (M.A.S., G.S.D., R.C., F.B.R., R.M.F., D.A., J.C., J.J.F.), Instituto de Medicina Molecular, Lisbon, Portugal; Huntington's Disease Centre (F.B.R.), Institute of Neurology, University College London, UK; Parkinson's Disease and Movement Disorders Center (T.M.), Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Canada; Paracelsus-Elena Klinik (C.T.), Center of Parkinsonism and Movement Disorders, Kassel; and the Department of Neurosurgery (C.T.), University Medical Center, Göttingen, Germany.
Abstract
To estimate the placebo and nocebo responses in restless legs syndrome (RLS) and explore their determinants.Databases were searched up to October 2015. Randomized, double-blind, placebo-controlled trials of patients with RLS were included if quantitative data were extractable in the placebo arm. Placebo response was defined as the within-group change from baseline, using any scale measuring RLS severity or disability. Nocebo response was defined as the proportion of patients experiencing adverse events in the placebo arm. Random-effects meta-analysis was used to pool data. Statistical heterogeneity was assessed with I(2) statistic. Several predetermined subgroup and sensitivity analysis were performed. PROSPERO registration number is CRD42015027992.We included 85 randomized controlled trials (5,046 participants). Pooled placebo response effect size was -1.41 (95% confidence interval [CI] -1.56 to -1.25, 64 trials, I(2) = 88.1%), corresponding to -6.58 points in the International RLS Study Group Scale (IRLS). Pooled nocebo response was 45.36% (95% CI 40.47%-50.29%, 72 trials; I(2) = 89.8%). The placebo and nocebo responses were greater in trials with longer duration, evaluating pharmacologic interventions and idiopathic RLS, and in industry-funded and unpublished studies. The placebo response was considerably smaller in objective as compared to subjective outcomes. In addition, the nocebo response increases proportionally with the placebo response, and has the same predictors.The magnitude of the placebo response in RLS is above the threshold of minimal clinical important difference, and the frequency of adverse events is also considerable. These results are relevant to inform the design and interpretation of future clinical trials.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
Author
Neurodegenerative Diseases
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by